Table 3.
One-way Sensitivity Analyses
| Category | Range | ICER for surgery ($/QALY) |
|---|---|---|
| Change in costs | ||
| Change in medical condition | ||
| Decrease to 25% | Double dose of PPI: $874.6 | 1479.5 |
| More than triple dose of PPI: $1167.5 | ||
| Increase to 25% | Double dose of PPI: $1457.7 | Dominate |
| More than triple dose of PPI: $1945.9 | ||
| Change in surgery condition | ||
| Decrease to 25% | First surgery: $4084.2 | 1362.4 |
| Surgery: $354.1 | ||
| Repeat-surgery: $3730.1 | ||
| Increase to 25% | First surgery: $6807.0 | Dominate |
| Surgery: $590.2 | ||
| Repeat-surgery: $6216.8 | ||
| Change in QALY | ||
| Commay et al, 200831 | Within one year after surgery: 0.981 | Dominate |
| Funk et al, 201525 | Surgery: 1.000 | |
| Symptom control with PPI: 0.990 | ||
| Symptom uncontrolled with PPI: 0.940 | ||
| Change in transition probability | ||
| Change in medical condition | ||
| Decrease to 25% | Symptom uncontrolled rate with medication: 0.012 | Dominate |
| Increase to 25% | Symptom uncontrolled rate with medication: 0.021 | Dominate |
| Change in surgery condition | ||
| Death due to surgery | Operative mortality: 0.008 19 | Dominate |
| Decrease to 25% | Repeat operation rate: 0.024 | Dominate |
| Symptom relapse rate after surgery: 0.005 | ||
| Increase to 25% | Repeat operation rate: 0.040 | Dominate |
| Symptom relapse rate after surgery: 0.009 |
ICER, incremental cost-effectiveness ratio; PPI, proton pump inhibitors; QALY, quality-adjusted life years.